Skip to main content
SpringerLink
Log in

Pazopanib monotherapy is associated with an increased risk of hand/foot skin reaction (HFSR),

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME.The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investigational New Drugs: 11 Mar 2011. Available from: URL: http://dx.doi.org/10.1007/s10637-011-9652-2

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pazopanib monotherapy is associated with an increased risk of hand/foot skin reaction (HFSR),. React. Wkly. 1352, 4 (2011). https://doi.org/10.2165/00128415-201113520-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113520-00011

Keywords

Search

Navigation